A Post-marketing Safety Study to Investigate the Risk of Serious CV Events among Galcanezumab (Emgality®) Users Using the Japan Medical Data Center Claim Database (I5Q-JE-B007) First published 11/04/2023 Last updated 23/04/2024 EU PAS number:EUPAS104412 Study Planned